On July 2, the U.S. Food and Drug Administration (FDA) approved Orkambi (lumacaftor 200 mg/ivacaftor 125 mg) for the treatment of cystic fibrosis (CF) in patients 12 years…
Reader Survey
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.